The FAMHP is addressing the concerns of healthcare professionals. To cope with the difficulties in supplying medicinal products, FAMHP experts are in constant contact with hospital pharmacies and are working tirelessly to find solutions. There is currently no shortage of medicinal products preventing the treatment of COVID-19 patients in Belgium.
Coronavirus: the FAMHP continues to supply essential medicinal products for intensive care and provides hospitals with daily updates
Following the recommendations of the Belgian National Security Council regarding the coronavirus epidemic, the FAMHP encourages employees to work more from home. Therefore, we ask all our partners to submit their files to us electronically as much as possible.
Following the coronavirus epidemic (COVID-19), experts at FAMHP are actively monitoring the potential impact on the availability of medication and medical devices in Belgium. The FAMHP is also supporting the European Medicines Agency (EMA) in developing COVID-19 vaccines.
The FAMHP launches PharmaStatus, the new online application that collects information about the availability of medicines in Belgium and makes it public. Current information will help patients, doctors, pharmacists and the pharmaceutical industry to limit the impact of unavailable medicines.
The fight against anti-microbial resistance continues: the Belgian BAPCOC 2019 antibiotics guide is available on the CBIP website
As recommended by the Belgian Health Care Knowledge Centre (KCE), a new step in the fight against anti-microbial resistance has been taken: the 2019 edition of the Belgian Antibiotic Policy Coordination Committee (BAPCOC)’s antibiotics guide is available online on the Belgian Pharmacotherapy Information Centre (CBIP) website.
The Vigilance Division of the FAMHP has found encoding errors in the article 57 database of the EMA. The FAMHP is asking holders of a marketing authorization for a medicine to carefully check that their registered data are correct.
The American Food and Drug Administration (FDA) has recognised the FAMHP as its Belgian counterpart under the mutual recognition agreement (MRA) between the European Union and the United States.
Until today, the good manufacturing practices (GMP) for medicinal products were only available in English. As of now, the GMP will be available in French and Dutch on the FAMHP website.
CESP (Common European Submission Portal), the European online system to exchange information between applicants of authorisations and competent authorities will have an update on 29 June 2018 to conform to the new General Data Protection Regulation (GDPR).
The federal agency for medicines and health products (famhp) will soon launch a first satisfaction survey to assess the quality of its services and products. The results of this will be communicated at the end of 2013 and will be used to improve the delivery of FAMHP services.